As of June 17, 2025, Genocea Biosciences Inc (GNCA) reports a ROE (Return on Equity) of -122.61%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Genocea Biosciences Inc's ROE (Return on Equity)
Over recent years, Genocea Biosciences Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-12-31 | -122.61% |
| 2020-12-31 | -486.68% |
| 2019-12-31 | -155.54% |
| 2018-12-31 | -379.15% |
| 2017-12-31 | 937.36% |
This slight upward trend highlights how Genocea Biosciences Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Genocea Biosciences Inc's ROE (Return on Equity) to Peers
To better understand Genocea Biosciences Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Genocea Biosciences Inc (GNCA) | -122.61% |
| Oragenics Inc (OGEN) | 4987.46% |
| GT Biopharma Inc (GTBP) | 788.14% |
| ContraFect Corp (CFRX) | 549.79% |
| CTI Biopharma Corp (CTIC) | 529.05% |
| Abbvie Inc (ABBV) | 128.66% |
Compared to its competitors, Genocea Biosciences Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.